Intra-Articular Corticosteroid or Hyaluronic Acid Injections Are Not Associated with Periprosthetic Joint Infection Risk following Total Knee Arthroplasty

Abstract

This study evaluated whether the preoperative use and timing of the use of hyaluronic acid (HA) and/or corticosteroid (CS) injections were associated with an increased risk of periprosthetic joint infections (PJIs) following primary total knee arthroplasty (TKA). We tested the hypothesis that preoperative injection of HA or CS within 3 months prior to primary TKA was associated with an increased risk of PJI by specifically evaluating the association between PJI risk and (1) injection type; (2) timing; (3) patient demographic factors; and (4) surgery-related factors, such as surgeon injection volume, knee arthroscopy (pre- and postoperative), and hospital length of stay. The 5% Medicare part B claims database was queried for patients who received CS and/or HA injections. Cox proportional hazards regressions evaluated the risk of PJIs after TKA, adjusting for patient and clinical factors, as well as propensity scores. The unadjusted incidence of PJI at 2-year post-TKA was 0.75% for the CS group, 0.89% for the HA group, 0.96% for both CS and HA group, and 0.75% for those who did not use HA or CS in the 12 months before TKA. For patients who used HA and/or CS within 3 months prior to TKA, the unadjusted incidence of PJI at 2-year post-TKA was 0.75% for the CS group, 1.07% for the HA group, and 1.00% for both CS and HA group, compared with 0.77% for those who did not use HA or CS. The number of injections performed per year was inconsistently associated with PJI risk. Overall, we found that intra-articular injections given within the 4-month period prior to TKA were not associated with elevated PJI risk (evaluated at 1, 3, 12, and 24 months after the index TKA) within the elderly Medicare patient population.

Keywords

total knee arthroplasty - periprosthetic joint infection - corticosteroid - hyaluronic acid - injections

• References

• 1 Mokdad AH, Ballestros K, Echko M. et al. US Burden of Disease Collaborators. The state of US health, 1990-2016: burden of diseases, injuries, and risk factors among US states. JAMA 2018; 319 (14) 1444-1472
• 2 GBD 2015 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016; 388 (10053): 1603-1658
• 3 Bortoluzzi A, Furini F, Scirè CA. Osteoarthritis and its management - Epidemiology, nutritional aspects and environmental factors. Autoimmun Rev 2018; 17 (11) 1097-1104
• 4 Hochberg MC, Altman RD, April KT. et al. American College of Rheumatology. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken) 2012; 64 (04) 465-474
• 5 Bedard NA, DeMik DE, Glass NA, Burnett RA, Bozic KJ, Callaghan JJ. Impact of clinical practice guidelines on use of intra-articular hyaluronic acid and corticosteroid injections for knee osteoarthritis. J Bone Joint Surg Am 2018; 100 (10) 827-834
• 6 Bhadra AK, Altman R, Dasa V. et al. Appropriate use criteria for hyaluronic acid in the treatment of knee osteoarthritis in the United States. Cartilage 2017; 8 (03) 234-254
• 7 Koenig KM, Ong KL, Lau EC. et al. The use of hyaluronic acid and corticosteroid injections among medicare patients with knee osteoarthritis. J Arthroplasty 2016; 31 (02) 351-355
• 8 Bedard NA, Pugely AJ, Elkins JM. et al. The John N. Insall award: do intraarticular injections increase the risk of infection after TKA?. Clin Orthop Relat Res 2017; 475 (01) 45-52
• 9 Cancienne JM, Werner BC, Luetkemeyer LM, Browne JA. Does timing of previous intra-articular steroid injection affect the postoperative rate of infection in total knee arthroplasty?. J Arthroplasty 2015; 30 (11) 1879-1882
• 10 Kokubun BA, Manista GC, Courtney PM, Kearns SM, Levine BR. Intra-articular knee injections before total knee arthroplasty: outcomes and complication rates. J Arthroplasty 2017; 32 (06) 1798-1802
• 11 Richardson SS, Schairer WW, Sculco TP, Sculco PK. Comparison of infection risk with corticosteroid or hyaluronic acid injection prior to total knee arthroplasty. J Bone Joint Surg Am 2019; 101 (02) 112-118
• 12 Manley M, Ong K, Lau E, Kurtz SM. Effect of volume on total hip arthroplasty revision rates in the United States Medicare population. J Bone Joint Surg Am 2008; 90 (11) 2446-2451
• 13 Lau RL, Perruccio AV, Gandhi R, Mahomed NN. The role of surgeon volume on patient outcome in total knee arthroplasty: a systematic review of the literature. BMC Musculoskelet Disord 2012; 13: 250
• 14 Werner BC, Burrus MT, Novicoff WM, Browne JA. Total knee arthroplasty within six months after knee arthroscopy is associated with increased postoperative complications. J Arthroplasty 2015; 30 (08) 1313-1316
• 15 Viste A, Abdel MP, Ollivier M, Mara KC, Krych AJ, Berry DJ. Prior knee arthroscopy does not influence long-term total knee arthroplasty outcomes and survivorship. J Arthroplasty 2017; 32 (12) 3626-3631
• 16 Kurtz SM, Ong KL, Lau E, Bozic KJ, Berry D, Parvizi J. Prosthetic joint infection risk after TKA in the Medicare population. Clin Orthop Relat Res 2010; 468 (01) 52-56
• 17 Son MS, Lau E, Parvizi J, Mont MA, Bozic KJ, Kurtz S. What are the frequency, associated factors, and mortality of amputation and arthrodesis after a failed infected TKA?. Clin Orthop Relat Res 2017; 475 (12) 2905-2913
• 18 Kurtz SM, Lau EC, Son MS, Chang ET, Zimmerli W, Parvizi J. Are we winning or losing the battle with periprosthetic joint infection: trends in periprosthetic joint infection and mortality risk for the Medicare population. J Arthroplasty 2018; 33 (10) 3238-3245
• 19 Inacio MC, Chen Y, Paxton EW, Namba RS, Kurtz SM, Cafri G. Statistics in brief: an introduction to the use of propensity scores. Clin Orthop Relat Res 2015; 473 (08) 2722-2726
• 20 Manley M, Ong K, Lau E, Kurtz SM. Total knee arthroplasty survivorship in the united states medicare population effect of hospital and surgeon procedure volume. J Arthroplasty 2009; 24 (07) 1061-1067
• 21 George J, Piuzzi NS, Ng M, Sodhi N, Khlopas AA, Mont MA. Association between body mass index and thirty-day complications after total knee arthroplasty. J Arthroplasty 2018; 33 (03) 865-871
• 22 Bozic KJ, Lau E, Kurtz S. et al. Patient-related risk factors for periprosthetic joint infection and postoperative mortality following total hip arthroplasty in Medicare patients. J Bone Joint Surg Am 2012; 94 (09) 794-800
• 23 Tan TL, Rajeswaran H, Haddad S, Shahi A, Parvizi J. Increased risk of periprosthetic joint infections in patients with hypothyroidism undergoing total joint arthroplasty. J Arthroplasty 2016; 31 (04) 868-871
• 24 Tan TL, Maltenfort MG, Chen AF. et al. Development and evaluation of a preoperative risk calculator for periprosthetic joint infection following total joint arthroplasty. J Bone Joint Surg Am 2018; 100 (09) 777-785
• 25 Cochran AR, Ong KL, Lau E, Mont MA, Malkani AL. Risk of reinfection after treatment of infected total knee arthroplasty. J Arthroplasty 2016; 31 (9, Suppl): 156-161
• 26 Bozic KJ, Chiu VW, Takemoto SK. et al. The validity of using administrative claims data in total joint arthroplasty outcomes research. J Arthroplasty 2010; 25 (6, Suppl): 58-61
• 27 Goldberg VMC, Coutts RD. Pseudoseptic reactions to hylan viscosupplementation: diagnosis and treatment. Clin Orthop Relat Res 2004; 419 (419) 130-137
• 28 Aydın M, Arıkan M, Toğral G, Varış O, Aydın G. Viscosupplementation of the knee: three cases of acute pseudoseptic arthritis with painful and irritating complications and a literature review. Eur J Rheumatol 2017; 4 (01) 59-62
• 29 Roos J, Epaulard O, Juvin R, Chen C, Pavese P, Brion JP. Acute pseudoseptic arthritis after intraarticular sodium hyaluronan. Joint Bone Spine 2004; 71 (04) 352-354